Join the club for FREE to access the whole archive and other member benefits.

Brian M. Culley

Mr. Culley occupies the position of President, CEO & Independent Director at Lineage Cell Therapeutics, Inc.

Brian M. Culley is a businessperson who has been at the head of 5 different companies. Mr. Culley occupies the position of President, CEO & Independent Director at Lineage Cell Therapeutics, Inc. and Chief Executive Officer of Asterias Biotherapeutics, Inc. Mr. Culley is also on the board of Orphagen Pharmaceuticals.
He previously was Chief Executive Officer & Director at Savara, Inc. and Chief Executive Officer & Director at Mast Therapeutics, Inc. Director-Business Development & Marketing at iTherX Pharmaceuticals, Inc., Chief Executive Officer at Artemis Therapeutics, Inc. and Licensing & Marketing Associate at the University of California, Berkeley.
He received a graduate degree from the University of California, Santa Barbara, an undergraduate degree from Boston College and an MBA from Johnson Graduate School of Management.


 brian-culley-7b219a1

 CEO_Culley

See also: Company Lineage Cell Therapeutics - Lineage is a clinical-stage biotechnology company developing novel cell therapies

Details last updated 31-Dec-2019

Brian M. Culley News

Longevity Technology interviews Lineage's CEO on the role of cell therapy in improving human longevity

Longevity Technology interviews Lineage's CEO on the role of cell therapy in improving human longevity

Longevity Technology - 03-Aug-2023

Details magic of converting stem cells to any cell type and transplanting them to treat age-related conditions

RPE-Cell therapy might potentially prevent blindness in dry AMD

RPE-Cell therapy might potentially prevent blindness in dry AMD

Biospace - 14-Jun-2021

Lineage CEO says “it offers a whole new paradigm to treat the disease”

Super summary of 3rd Annual Longevity Therapeutics Summit

Super summary of 3rd Annual Longevity Therapeutics Summit

Lifespan.io (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year

Method of Generating Induced Pluripotent Stem Cells

Method of Generating Induced Pluripotent Stem Cells

Longevity Technology - 10-Dec-2019

New reprogramming technology could provide an alternate source of material needed for therapies